A first-in-human study reports that roginolisib, a conformation-selective PI3Kδ inhibitor, is tolerable in advanced cancers, with survival signals reported in metastatic uveal melanoma. The trial also describes immune changes consistent with relief of tumor-induced immunosuppression. The development targets a specific PI3Kδ conformational state, differentiating it from broader PI3K pathway inhibition approaches. For biotech observers, it highlights how next-generation PI3Kδ inhibitors are being positioned not only for direct tumor effects but also for immune modulation. While efficacy conclusions are limited by early trial design, the safety profile and median overall survival reported in a subgroup provide a rationale for continued clinical expansion and combination strategies.